MariTide
Regulatory
Legal Status in 2026
In active US clinical trials (Phase 2 or later); no FDA approval yet.
This compound is under active investigation in US clinical trials (Phase 2 or later) and has not yet received FDA approval. It is not legally available for prescription or compounding outside of enrolled clinical trial settings. The risk-benefit profile is not yet established for the general population.
About
About MariTide
MariTide (AMG 133) is a GIP receptor antagonist / GLP-1 receptor agonist fusion molecule developed by Amgen with a monthly dosing interval — the longest injection interval of any obesity therapeutic in development. Phase II data showed 20% weight loss at 52 weeks. Its monthly convenience and potent efficacy position it as a potential market disruptor if Phase III results confirm Phase II findings.
Science
Mechanism of Action
Simultaneously blocks GIP receptors (antagonism, unlike tirzepatide's agonism) and activates GLP-1 receptors; the GIP antagonism enhances GLP-1-mediated weight loss through incompletely understood mechanisms involving adipose tissue and CNS receptor cross-talk.
Dosing
Typical Protocol
Monthly subcutaneous injection; Phase II dose range not disclosed; Phase III initiated 2024.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Availability
Provider availability
MariTide is in active clinical trials and is not available through legitimate US prescribing or compounding channels outside an enrolled trial, so Vial does not list providers for it.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.